As alcohol Prohibition ended 86 years ago today, illicit revenue became legal profits available to savvy investors, a flood of researched-based innovation drove new products, and the industry soared. This is all happening in the cannabis industryright now.
Epidolex may be the first FDA-approved, cannabis-based pharma product on the market. But over-the-counter, hemp-based CBD products will take a large bite out of that market as it continues to show similar effects as the price, prescription-based brand.
Not all IPOs are created equal. The biggest winners, the next Tilray, are going to thrive in at least one of three key areas of focus. These are areas where companies can truly differentiate themselves from the crowd.
It's difficult to see a stock you recently bought go down. But as those who sold during Canopy Growth's three significant declines dating back to 2015 would attest, now is not the time to lose our resolve.
With 2019 right around the corner, three key themes stand out far beyond any other topics that will shape the business end of the marijuana industry. That includes perhaps the most shocking emerging target demographic for cannabis to date.
There is a reason the adage "you get what you pay for" exists. Dozens of financial information websites put out a lot of misleading information, especially when it comes to cannabis companies that are new or making a lot of deals.
Stocks are likely to post much bigger gains when the possibility of something (e.g., a law change, a merger or acquisition, etc.) first becomes known. Once the event actually happens, many investors have already moved on or may even be looking to take some gains (sell off the stocks they bought in advance of or right as a rumor came out). Three new indices show this very thing.
The best emerging cannabis stock opportunities right now don’t involve companies listed on the New York Stock Exchange or Nasdaq. Fortunately, most of the biggest U.S-based brokers now allow you to trades stocks listed in Canada, notably ones on the Toronto Stock Exchange (TSX) and the Canadian Securities Exchange (CSE).
More than $42 billion is spent annually on medical and psychiatric care. And with treatments like opioids increasingly out of favor, Americans - especially veterans suffering from PTSD - are looking for safe, reliable alternatives. And cannabis more than any other substance is ready to fill that void.